Robert Michel
Until Robert L. Michel came along and founded The Dark Intelligence Group (DIG) two decades ago, the clinical laboratory industry and the anatomic pathology profession lacked a trustworthy source for information about the management and operations of medical laboratories. From its inception in 1995, The Dark Report quickly became the “go to” source of industry intelligence, innovations in lab management, and strategic market analysis.
This excellence in reporting has earned recognition from his peers. For example, twice Michel and The Dark Report have won national awards for best investigative reporting by the Specialty Information Publishers Association. In 2005, the award was for Michel’s coverage about how the anatomic pathology condominium laboratories (pod labs) operated by urologists and gastroenterologists came to be, who operated them, and how these owners marketed the AP condo labs to other physician groups. In 2009, Michel’s award for best investigative reporting resulted from his published interviews with Quest Diagnostics Incorporated when the company admitted that, for a period of 18 months, it had been reported inaccurate Vitamin 25(OH) D results because of problems with its laboratory-developed test methodology. The Dark Report’s story was picked up by The New York Times and was in the national news cycle for several days.
In his role as Editor-in-Chief, Michel brought unique capabilities to DIG and The Dark Report. His management training and diverse business experience—along with his skills as a concise writer and analyst—proved to be a winning combination for readers of The Dark Report. For that reason, Michel’s story has many intriguing elements.
Immediately prior to founding DIG, he had served in several executive positions for Nichols Institute based in Portland, Oregon, and San Juan Capistrano, California. This was during the time that Nichols Institute was an independent public lab company with annual revenues of about $280 million (prior to its acquisition by MetPath, Inc., now Quest Diagnostics Incorporated). He traveled extensively to many of the clinical lab business units owned by Nichols Institute in different regions of the United States and played a role in formulating effective market strategies in response to the emergence of closed-panel HMOs, capitated pricing, and full-risk managed care contracts, among other successful management initiatives.
Prior to his service at Nichols Institute, Michel served at three different Fortune 100 companies. These were Procter & Gamble, Centex Corporation, and Financial Corp. of America. Each was an opportunity to master new management techniques and apply them in different industries. Between these positions, he gained experience as an entrepreneur, having founded a real estate development firm and a general contracting company in the Southeastern United States.
Robert Michel earned a Bachelor of Arts degree in Economics at the University of California, Los Angeles, where he played rugby, a sport he participated in for another 22 years. He is a native of California and grew up in Santa Ana.
Articles by Robert Michel
Executive War College to Show New Opportunities for Labs
From the Volume XXVIII, No. 13 – September 27, 2021 Issue
CEO SUMMARY: Yes, the pandemic continues and hospitals are running short of beds in many communities. At the same time, 225 million Americans are either vaccinated or have some immunity to COVID-19. Based on the early registrations to attend the 27th annual Executive War College, it…
New Class of IVD Firms Wants to Serve POCT in Near-Patient Settings
From the Volume XXVIII, No. 13 – September 27, 2021 Issue
CEO SUMMARY: Our second installment in this series describes an emerging new clas…
MedPAC Reports to Congress on Issues in Lab Test Price Survey
From the Volume XXVIII, No. 13 – September 27, 2021 Issue
IN THE HALLS OF CONGRESS, A GOOD NEWS/BAD NEWS STORY is unfolding around the multi-year cuts to the prices Medicare pays for clinical laboratory tests. First the good news. In its latest semi-annual report to Congress, the Medicare Payment …
September 27, 2021 Intelligence: Late-Breaking Lab News
From the Volume XXVIII, No. 13 – September 27, 2021 Issue
Following the opening of her criminal trial in a Silicon Valley courtroom in recent weeks, Elizabeth Holmes—the disgraced ex-Founder and CEO of Theranos—continues to be the subject of news headlines. Federal prosecutors are calling witnesses to testify. Much of this testimony includes anec…
All Labs Are Threatened by Encryption, Ransomware
From the Volume XXVIII, No. 12 – September 7, 2021 Issue
CEO SUMMARY: Cybercrime—in the form of encryption attacks followed by ransom demands—is now a threat to every clinical laboratory and anatomic pathology group in the United States. Experts recommend that all labs elevate the attention they pay to their incident response teams ta…
All Labs Are Threatened by Ransomware Attacks
From the Volume XXVIII, No. 12 – September 7, 2021 Issue
This is an excerpt of a 1,652-word article in the September 7, 2021 issue of THE DARK REPORT (TDR). The full article is available to members of The Dark Intelligence Group. CEO SUMMARY: Cybercrime—in the form of encryption attacks followed by ransom demands—is now a threat to…
PathAI Buys Poplar Health, Creates Unique Company
From the Volume XXVIII, No. 12 – September 7, 2021 Issue
CEO SUMMARY: Pathologists were surprised this summer when a company developing image analysis software announced the acquisition of one of the nation’s largest independent anatomic pathology (AP) laboratories. The technology company PathAI is now the owner of Poplar Healthcare Man…
Lab Briefs
From the Volume XXVIII, No. 12 – September 7, 2021 Issue
DOJ Obtains $140 Mil. Settlement in Drug Testing Case Last Friday, the U.S. Department of Justice (DOJ) announced a settlement totaling $136,025,077 with multiple defendants accused of using illegal inducements to encourage physicians to re…
NeoGenomics Acquires Inivata to Access Liquid Biopsy Technology
From the Volume XXVIII, No. 12 – September 7, 2021 Issue
SOME BELIEVE THAT LIQUID BIOPSY TECHNOLOGY has the potential to develop into a Holy Grail of cancer diagnostics. Yet progress in this field has been slow. Now a recent lab acquisition may accelerate the development of clinically-useful liquid biopsies. There is keen interest in how to achieve the …
UK Hospitals to Deploy AI to Speed Prostate Cancer Diagnoses
From the Volume XXVIII, No. 12 – September 7, 2021 Issue
SEEKING TO SPEED UP THE PRODUCTION OF TEST RESULTS for men suspected of having prostate cancer, six hospitals in the United Kingdom (UK) will get funding to determine if artificial intelligence (AI) can diagnose prostate cancer quicker and more accurately than pathologists….
CURRENT ISSUE

Volume XXXII, No. 13 – September 15, 2025
The Dark Report examines a new bill that would reform PAMA and avoid reimbursement rate cuts scheduled for January 2026. Clinical laboratory leaders are urged to make their voices heard in Congress. Also, an expert describes how labs can fix pre-analytical errors and avoid disaster.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized